HK2894A - Eicosapentaenoic acid - Google Patents

Eicosapentaenoic acid

Info

Publication number
HK2894A
HK2894A HK28/94A HK2894A HK2894A HK 2894 A HK2894 A HK 2894A HK 28/94 A HK28/94 A HK 28/94A HK 2894 A HK2894 A HK 2894A HK 2894 A HK2894 A HK 2894A
Authority
HK
Hong Kong
Prior art keywords
lipolytic
mammals
polyunsaturated fatty
activity
eicosapentaenoic acid
Prior art date
Application number
HK28/94A
Other languages
English (en)
Inventor
Michael John Tisdale
Susan Anne Beck
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of HK2894A publication Critical patent/HK2894A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
HK28/94A 1989-03-20 1994-01-13 Eicosapentaenoic acid HK2894A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898906369A GB8906369D0 (en) 1989-03-20 1989-03-20 Eicosapentaenoic acid
SG137193A SG137193G (en) 1989-03-20 1993-12-21 Eicosapentaenoic acid

Publications (1)

Publication Number Publication Date
HK2894A true HK2894A (en) 1994-01-21

Family

ID=26295116

Family Applications (1)

Application Number Title Priority Date Filing Date
HK28/94A HK2894A (en) 1989-03-20 1994-01-13 Eicosapentaenoic acid

Country Status (11)

Country Link
EP (1) EP0464084B1 (xx)
JP (1) JP3010310B2 (xx)
AT (1) ATE155037T1 (xx)
AU (1) AU643201B2 (xx)
DE (1) DE69031033T2 (xx)
DK (1) DK0464084T3 (xx)
ES (1) ES2103738T3 (xx)
GB (2) GB8906369D0 (xx)
HK (1) HK2894A (xx)
SG (1) SG137193G (xx)
WO (1) WO1990011073A1 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000084A1 (en) * 1991-06-24 1993-01-07 Adelaide Children's Hospital Methods and compositions for treating malaria and other diseases
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
TR199900786T2 (xx) 1996-10-11 1999-07-21 Scotia Holdings Plc Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler.
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2449199A1 (en) * 2001-05-30 2002-12-05 Laxdale Limited Coenzyme q and eicosapentaenoic acid (epa)
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP2025248A1 (en) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Cachexia prevention supplement
WO2009149496A1 (en) * 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR20140007973A (ko) 2009-02-10 2014-01-20 아마린 파마, 인크. 고중성지방혈증 치료 방법
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN102625847A (zh) 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
SG10201913645RA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201827047A (zh) 2016-12-23 2018-08-01 挪威商普諾瓦生物製藥挪威公司 用於預防及/或治療惡病質的ω-3脂肪酸組合物
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51765A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1933383A (en) * 1982-09-22 1984-03-29 Sentrachem Limited Composition of prostaglandins for prevention of cancer
AU4595985A (en) * 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
JPS63303925A (ja) * 1987-06-05 1988-12-12 Nippon Oil & Fats Co Ltd 制癌剤組成物
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids

Also Published As

Publication number Publication date
GB8906369D0 (en) 1989-05-04
DK0464084T3 (da) 1997-08-11
JP3010310B2 (ja) 2000-02-21
AU5331090A (en) 1990-10-22
WO1990011073A1 (en) 1990-10-04
EP0464084A1 (en) 1992-01-08
AU643201B2 (en) 1993-11-11
EP0464084B1 (en) 1997-07-09
GB2229363A (en) 1990-09-26
ATE155037T1 (de) 1997-07-15
GB9006256D0 (en) 1990-05-16
GB2229363B (en) 1993-06-02
SG137193G (en) 1994-03-31
JPH05504936A (ja) 1993-07-29
DE69031033D1 (de) 1997-08-14
ES2103738T3 (es) 1997-10-01
DE69031033T2 (de) 1997-11-20

Similar Documents

Publication Publication Date Title
GB2229363B (en) Eicosapentaenoic acid
WO1997039759A3 (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
PL338219A1 (en) Therapeutic and dietary compositions containing necessary unsaturated fatty acids and biologically active disulphides
IL137848A0 (en) Indole-3-propionic acids, salts and esters thereof used as medicaments
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
Kabara Health oils from the tree of life
EP0764405A3 (en) Nutritional composition
EP0295331A3 (en) Use of vitamin e for normalizing the blood coagulation in the therapy with omega-3-type highly unsaturated fatty acids
DE3379568D1 (en) Surfactant treatment of implantable biological tissue to inhibit calcification
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
IL136101A (en) Pharmaceutical compositions containing azelaic acid
FI850354L (fi) Kompositioner foer anvaendning vid kosmetisk, haelso- och kroppsvaord.
GB2210789A (en) Topical application for skin care
US5891083A (en) Suction lipolysis
CA2052577A1 (en) Therapeutic uses of eicosapentaenoic acid
ATE110274T1 (de) Mittel zur verbesserung spezifischer eigenschaften des blutes.
ES8205190A1 (es) Un procedimiento para la preparacion del acido 3,7,11,15-tetrametil-2,4,6,10-14-hexadecapentaenoico.
SE8800990L (sv) Hudregenererande kosmetisk komposition samt foerfarande foer framstaellning av densamma
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
Murrell II. Scientific comment basic science of Dupuytren's disease
RU2040251C1 (ru) Косметическое средство р.н.караева для ухода за кожей лица и тела
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
Higaki et al. Effect of Kampoh crude drugs on Propionibacterium acnes lipase activity
Tsuji et al. Age-associated changes of the levels of superoxide dismutase and lipid peroxide, and the damaging effects of an oxygen radical on the hairless rat skin
Chen et al. Synergistic effect of hyperthermia and TNF on endothelioma cell (F-2) killing

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060320